OncoImmune, Pfizer deal

OncoImmune granted Pfizer an exclusive option to license rights to ONC-392, a preclinical mAb against cytotoxic T-lymphocyte associated protein 4 ( CTLA4; CD152), and additional anti-CTLA4 antibodi...